Researchers explored the effectiveness of combination levatinib, a multitargeted tyrosine kinase inhibitor (TKI), plus pembrolizumab, an anti-PD-1 monoclonal antibody, as a first-line treatment for advanced or recurrent EC. The combination of...
Researchers explored the effectiveness of combination levatinib, a multitargeted tyrosine kinase inhibitor (TKI), plus pembrolizumab, an anti-PD-1 monoclonal antibody, as a first-line treatment for advanced or recurrent EC. The combination of...
Researchers explored the...